Mucuna Pruriens Combined with Carbidopa in Parkinson's Disease: A Case Report
- Resource Type
- Authors
- Andreas T Tiel Groenestege; Bastiaan R. Bloem; Eline W. Muilwijk; Danique L.M. Radder; Inge Boers
- Source
- Journal of Parkinson's Disease, 9, 437-439
Journal of Parkinson's Disease, 9, 2, pp. 437-439
- Subject
- 0301 basic medicine
Levodopa
Parkinson's disease
Pharmacology
03 medical and health sciences
Cellular and Molecular Neuroscience
0302 clinical medicine
Medicine
Aromatic Amino Acid Decarboxylase Inhibitors
Humans
biology
business.industry
Carbidopa
Parkinson Disease
Patient Preference
Middle Aged
biology.organism_classification
medicine.disease
Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]
Mucuna
030104 developmental biology
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]
Tolerability
Drug Therapy, Combination
Female
Neurology (clinical)
Plant Preparations
business
030217 neurology & neurosurgery
Mucuna pruriens
medicine.drug
Phytotherapy
- Language
- ISSN
- 1877-7171
Contains fulltext : 205178.pdf (Publisher’s version ) (Closed access) We present a 48-year-old woman with Parkinson's disease in whom carbidopa was added to Mucuna pruriens, resulting in marked motor improvement (documented on video and using MDS-UPDRS motor scores). This case report shows that adding a dopa-decarboxylase inhibitor (DDCI) to Mucuna pruriens could fit well in a personalized approach for patients who are reluctant to start levodopa. Meanwhile, larger trials with a longer follow-up are needed to establish the true effects and tolerability of Mucuna pruriens plus a DDCI.